Cargando…

Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy

OBJECTIVE: To examine the clinicopathologic factors that contribute to regional and distant recurrence in intermediate to high risk head and neck melanoma patients after sentinel lymph node biopsy (SLNB). METHODS: This study is a retrospective review from an academic tertiary care center. Patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Echanique, Kristen A., Ghazizadeh, Shabnam, Moon, Andy, Kwan, Kera, Pellionisz, Peter A., Rünger, Dennis, Elashoff, David, St. John, Maie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356881/
https://www.ncbi.nlm.nih.gov/pubmed/34401498
http://dx.doi.org/10.1002/lio2.605
_version_ 1783737028912873472
author Echanique, Kristen A.
Ghazizadeh, Shabnam
Moon, Andy
Kwan, Kera
Pellionisz, Peter A.
Rünger, Dennis
Elashoff, David
St. John, Maie
author_facet Echanique, Kristen A.
Ghazizadeh, Shabnam
Moon, Andy
Kwan, Kera
Pellionisz, Peter A.
Rünger, Dennis
Elashoff, David
St. John, Maie
author_sort Echanique, Kristen A.
collection PubMed
description OBJECTIVE: To examine the clinicopathologic factors that contribute to regional and distant recurrence in intermediate to high risk head and neck melanoma patients after sentinel lymph node biopsy (SLNB). METHODS: This study is a retrospective review from an academic tertiary care center. Patients treated with SLNB for head and neck melanoma from 1997 to 2019 were reviewed and characterized by sentinel lymph node (SLN) status. Clinical variables were examined for the impact on regional and distant recurrence in SLNB‐negative patients using univariable and multivariable Cox regression analysis. RESULTS: One hundred and fifty four patients were included. Of note, 127 (82.5 %) were men, and the average age was 61.3 years. Median follow‐up was 68.6 weeks. Pathologic review of SLNs found 3.9% positive for metastatic melanoma; 96.1% were negative. Regional recurrence was significantly associated with tumor stage and age on multivariate analysis. A total of 4.5% of patients recurred in a previously labeled negative basin. Scalp subsite accounted for 30.5% of primary tumors and was more likely to yield a positive SLN on univariate analysis (P = .023). Tumor stage and age were significantly associated with distant metastasis on multivariable analysis (P = .026, P < .001 respectively). CONCLUSION: We report a number of prognostic trends in head and neck melanoma. SLN positivity was found more often in patients with a primary tumor of the scalp. Regional recurrence was significantly associated with age and tumor stage, whereas distant recurrence was significantly associated with tumor staging and scalp subsite. Scalp subsite was associated with an increased risk for nodal metastasis and distant recurrence. LEVEL OF EVIDENCE: 3.
format Online
Article
Text
id pubmed-8356881
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-83568812021-08-15 Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy Echanique, Kristen A. Ghazizadeh, Shabnam Moon, Andy Kwan, Kera Pellionisz, Peter A. Rünger, Dennis Elashoff, David St. John, Maie Laryngoscope Investig Otolaryngol HEAD AND NECK, AND TUMOR BIOLOGY OBJECTIVE: To examine the clinicopathologic factors that contribute to regional and distant recurrence in intermediate to high risk head and neck melanoma patients after sentinel lymph node biopsy (SLNB). METHODS: This study is a retrospective review from an academic tertiary care center. Patients treated with SLNB for head and neck melanoma from 1997 to 2019 were reviewed and characterized by sentinel lymph node (SLN) status. Clinical variables were examined for the impact on regional and distant recurrence in SLNB‐negative patients using univariable and multivariable Cox regression analysis. RESULTS: One hundred and fifty four patients were included. Of note, 127 (82.5 %) were men, and the average age was 61.3 years. Median follow‐up was 68.6 weeks. Pathologic review of SLNs found 3.9% positive for metastatic melanoma; 96.1% were negative. Regional recurrence was significantly associated with tumor stage and age on multivariate analysis. A total of 4.5% of patients recurred in a previously labeled negative basin. Scalp subsite accounted for 30.5% of primary tumors and was more likely to yield a positive SLN on univariate analysis (P = .023). Tumor stage and age were significantly associated with distant metastasis on multivariable analysis (P = .026, P < .001 respectively). CONCLUSION: We report a number of prognostic trends in head and neck melanoma. SLN positivity was found more often in patients with a primary tumor of the scalp. Regional recurrence was significantly associated with age and tumor stage, whereas distant recurrence was significantly associated with tumor staging and scalp subsite. Scalp subsite was associated with an increased risk for nodal metastasis and distant recurrence. LEVEL OF EVIDENCE: 3. John Wiley & Sons, Inc. 2021-06-21 /pmc/articles/PMC8356881/ /pubmed/34401498 http://dx.doi.org/10.1002/lio2.605 Text en © 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC. on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle HEAD AND NECK, AND TUMOR BIOLOGY
Echanique, Kristen A.
Ghazizadeh, Shabnam
Moon, Andy
Kwan, Kera
Pellionisz, Peter A.
Rünger, Dennis
Elashoff, David
St. John, Maie
Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
title Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
title_full Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
title_fullStr Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
title_full_unstemmed Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
title_short Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
title_sort head & neck melanoma: a 22‐year experience of recurrence following sentinel lymph node biopsy
topic HEAD AND NECK, AND TUMOR BIOLOGY
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356881/
https://www.ncbi.nlm.nih.gov/pubmed/34401498
http://dx.doi.org/10.1002/lio2.605
work_keys_str_mv AT echaniquekristena headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy
AT ghazizadehshabnam headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy
AT moonandy headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy
AT kwankera headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy
AT pellioniszpetera headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy
AT rungerdennis headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy
AT elashoffdavid headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy
AT stjohnmaie headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy